Juan Carlos Jaume (Juan C Jaume, Juan Jaume)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Cardiovascular Disease

Patients Undergoing

Top Venues

The Journal of clinical endocrinology and metabolism

Antioxidants (Basel, Switzerland)

Journal of diabetes

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Rodis Paparodis, Sarantis Livadas, Evangelos Karvounis, Dimitra Bantouna, Ioannis Zoupas, Nicholaos Angelopoulos, Shahnawaz Imam, Juan Carlos Jaume
Elevated Preoperative TPO Ab Titers Decrease Risk for DTC in a Linear Fashion: A Retrospective Analysis of 1,635 cases. The Journal of clinical endocrinology and metabolism (2023)
Mohammed A Madkhali, Jenifer-Kris Hao, Mohammed Saud Khan, Himani Sharma, Alexa Jaume, Abhinav Tiwari, Shahnawaz Imam, Juan Carlos Jaume
Intractable Seizures and Limbic Encephalitis, Unaccounted Complications of Type 1 Diabetes Autoimmunity. Journal of the Endocrine Society 6 (2) (2022)
Rodis D Paparodis, Evangelos Karvounis, Dimitra Bantouna, Charilaos Chourpiliadis, Hara Hourpiliadi, Sarantis Livadas, Shahnawaz Imam, Juan Carlos Jaume
Large, Slowly Growing, Benign Thyroid Nodules Frequently Coexist With Synchronous Thyroid Cancers. The Journal of clinical endocrinology and metabolism 107 (8) (2022)
Jiahui Zhang, Fnu Anshul, Deepak K Malhotra, Juan Carlos Jaume, Lance D Dworkin, Rujun Gong
Microdose Lithium Protects against Pancreatic Islet Destruction and Renal Impairment in Streptozotocin-Elicited Diabetes. Antioxidants (Basel, Switzerland) 10 (1) (2021)
Shahnawaz Imam, Pervaiz Dar, Rodis Paparodis, Khalil Almotah, Ahmed Al-Khudhair, Syed Abdul-Moiz Hasan, Nancy Salim, Juan Carlos Jaume
Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer. Journal for immunotherapy of cancer 7 (1) (2019)
Sharifa Alhassan, Michael Rudoni, Maria A Alfonso-Jaume, Juan Carlos Jaume
Protracted glycosuria after discontinuation of sodium-glucose cotransporter 2 inhibitors: Implications for weekly dosing and extended risk of euglycemic diabetes ketoacidosis. Journal of diabetes 11 (5) (2019)